JUNB and chronic myelogenous leukemia, BCR-ABL1 positive: Mechanism studies have shown that the CpG site in the JunB promoter region of CML patients is highly methylated, and 5-aza-2-deoxycytidine demethylation can partially restore the expression level of JunB, indicating that JunB methylation may be a cause leading to CML (Yang et al., 2003).